Insufficient evidence to show benefit of Glybera in lipoprotein lipase deficiency patients with severe or multiple pancreatitis attacks.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) at its April 2012 meeting maintained its recommendation not to grant a marketing authorisation for the orphan medicine Glybera (alipogene tiparvovec), from Amsterdam Molecular Therapeutics B.V.

Posted on the EMA website, 20 April 2012